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RATIONALE:Manypatients with adenocarcinoma of the prostate presentwith advanced andmetastatic cancer at the time
of diagnosis. There is an urgent need to detect biomarkers that will improve the diagnosis and prognosis of this disease.
Matrix-assisted laser desorption/ionization imaging mass spectrometry (MALDI-IMS) is playing a key role in cancer
research and it can be useful to unravel the molecular profile of prostate cancer biopsies.
METHODS: MALDI imaging data sets are highly complex and their interpretation requires the use of multivariate
statistical methods. In this study, MALDI-IMS technology, sequential principal component analysis (PCA) and
two-dimensional (2-D) peak distribution tests were employed to investigate tumor heterogeneity in formalin-fixed
paraffin-embedded (FFPE) prostate cancer biopsies.
RESULTS: Multivariate statistics revealed a number of mass ion peaks obtained from different tumor regions that were
distinguishable from the adjacent normal regions within a given specimen. These ion peaks have been used to generate
ion images and visualize the difference between tumor and normal regions. Mass peaks at m/z 3370, 3441, 3447 and
3707 exhibited stronger ion signals in the tumor regions.
CONCLUSIONS: This study reports statistically significant mass ion peaks unique to tumor regions in adenocarcinoma of
the prostate and adds to the clinical utility ofMALDI-IMS for analysis of FFPE tissue at amolecular level that supersedes all
other standard histopathologic techniques for diagnostic purposes used in the current clinical practice. Copyright © 2016
John Wiley & Sons, Ltd.
Since its inception twenty years ago, matrix-assisted laser
desorption/ionization imaging mass spectrometry (MALDI-
IMS) has matured as a powerful tool that provides new
insights into the molecular physiopathology of diseases.[1–3]
The technique is widely used in biomedical research to
profile the distribution of proteins, peptides, and small
molecules on tissue.[4–6] In addition, MALDI-IMS provides
reproducible high-resolution mass measurements of
molecules in complex biological matrices such as cells and
serum samples.[7,8] MALDI-IMS plays a key role in the
discovery of biomarkers for the diagnosis of cancer and
classification of the disease pathology.[9,10] Given its ability
to localize proteins and smaller molecules across an entire
tissue section, MALDI-IMS analysis holds promise in the
elucidation of molecular processes in the tumor
microenvironment.[11]
Comprehensive visualization of distribution of
biomolecules across tissue sections by defining peptide ions
specific for various tumor regions may improve the
classification and prognosis of cancer.[12–14] Here we describe
the use of sequential principal component analysis (PCA) of
MALDI-IMS data sets to unveil the molecular profile in
formalin-fixed paraffin-embedded (FFPE) tissues of
adenocarcinoma of the prostate. Adenocarcinoma of the
prostate is the most common type of prostate cancer
(PCa).[15,16] However, it is a type of cancer with a wide range
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of behavior from cases which are very slow growing to cases
which are more aggressive and many patients present with
advanced and metastatic cancer at the time of diagnosis.[17]
Thus, there is an urgent need to identify biomarkers that will
improve the diagnosis and prognosis of this disease.[18]
The ability of MALDI-IMS to localize molecular changes
within a tissue section at a cellular level and to allow for
accurate positive, differential and exclusion diagnosis of a
given disease can significantly improve the diagnosis of
PCa.[19] A number of studies have been carried out to search
for biomarkers for PCa diagnosis in various biomaterials.[20–22]
Recently, MALDI -MS profiling of serum proteins
demonstrated the ability to discriminate PCa patients’
profiles from control samples.[23] MALDI-time-of-flight
(TOF)-MS protein profiles of urine samples of healthy
donors have been compared with prostate cancer patients
for a differential proteomic study.[24] Matrix coating assisted
by an electric field (MCAEF) has been used for overall
enhancement of MALDI-IMS analysis of human prostate
cancer biomarkers.[25] However, only a limited number of
studies were performed at a molecular level using
MALDI-IMS for a direct tissue correlated proteome
analysis.[26] Some potential PCa biomarkers have been
reported using MALDI-IMS analysis of fresh-frozen prostate
cancer tissues.[27–32] The major disadvantage of using
fresh-frozen tissues is the limited availability of tissues for
which clinical follow-up data are available. The major
source of tissue samples are FFPE tissues found in hospital
archives and their use helps to alleviate many of the
problems associated with frozen tissues.[33] In addition,
FFPE tissues are much easier to store and transport because
they are stable at room temperature so methods and
technologies that permit analysis of large numbers of such
samples are essential.[34] Several protocols for heat-induced
antigen retrieval (HIAR) have previously been established
that allow MALDI-IMS studies in various FFPE tissue
types.[35–37] However, it is currently well known that
although these protocols are applicable to many tissue
types, to achieve optimal results, the HIAR procedure for
each different tissue type should be optimized.[38,39]
Recently, tissue microarray technology in combination with
MALDI-IMS operated in positive reflectron mode over the
mass-to-charge (m/z) range of 500–3680 has been employed
to identify molecular features associated with clinico-
pathological parameters in FFPE prostate cancer tissues.[40]
Given this development the employment of a MALDI-IMS
method in positive linear mode over the m/z range of
2000–20,000 to analyze FFPE prostate tissue biopsies would
be of great clinical value.
To the best of our knowledge this is the first time that a
multivariate statistical approach based on sequential PCA
has been proposed for a direct tissue correlated proteome
analysis of FFPE prostate cancer biopsies using MALDI-IMS.
In this study FFPE samples were processed using a HIAR
procedure to restore normal protein composition and increase
the signal and the number of mass ion peaks detected with
Figure 1. Experimental workflow for imaging biomolecules in prostate cancer FFPE tissues.
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Figure 2. (A)MALDI ion images of normal and tumor sections of FFPE case 1 form/z 3441 and 6012 showing the
selected ROIs. PCA score and loading plots of tumor and normal ROIs (B, D, F) with their analogous 2-D
distribution plots (C, E, G). Non-tumor ROIs N1 to N4 (blue), tumor ROIs T1 (bright green), T2 (dark green),
T3 (red), T4 (brown), and T5 (pink).
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Figure 3. (Α) Average mass spectra of FFPE case 1 processed with TRIS buffer pH 9. (B) Pseudo-gel
views of tumor ROIs T1 to T5 and normal ROIs N1 and N2. The x-axis indicates m/z mass value and
y-axis is the spectra number used to produce the average mass value. Peak intensities are indicated
as arbitrary units in the right intensity gradient.
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MALDI-IMS. Due to the high complexity of MALDI imaging
data sets their interpretation requires the use of multivariate
statistical methods to reduce data dimensionality and
determine the components that correlate to the classification
of the data.[41–44] Therefore, the data analysis in this study
was performed using sequential PCA so as to identify and
classify the ion peaks that allowed the accurate differentiation
of samples. PCA carries out linear orthogonal transformation
of the data to maximize variance, resulting in a set of
orthogonal principal components that describe the largest
variance in the dataset.[45–47] The results underline the vast
potential of MALDI-IMS in combination with PCA to detect
molecular patterns suitable to distinguish between tumor
and normal prostate tissues. These specific and statistically
significant ion peaks may serve as potential biomarkers for
adenocarcinomaof the prostate in FFPE tissue section samples.
EXPERIMENTAL
Materials
All solvents used were of HPLC grade and purchased from E.
Merck (Darmstadt, Germany). Xylenewas of analytical reagent
grade and purchased from J.T. Baker (Phillipsburg, NJ, USA).
Conductive indium tin oxide (ITO) one-side coated glass slides
and peptide calibration standard II were purchased from
Bruker Daltonik GmbH (Billerica, MA, USA). Sinapinic acid
(SA) was purchased from Sigma-Aldrich (St. Louis, MO, USA).
Sample collection
Prostate tissues were collected with the consent of patients
undergoing surgery at the Rhode Island Hospital in
Providence, RI, USA. In this pilot study, FFPE tissues of two
patients (case 1 and case 2) with adenocarcinoma of the
prostate were used. Normal areas were also used as reference
controls. The tissue samples were removed by surgery
according to the standard local therapeutic protocol.
Pathological appearances of the tissue samples were
microscopically determined by an experienced pathologist.
Sample preparation
FFPE samples were fixed in 10% buffered formalin for 24 h,
at room temperature, dehydrated with ethanol and paraffin-
embedded according to the standard local protocol. The
samples were cut into 4-μm tissue sections using a Leica
RM2125RT microtome operated at room temperature and
applied onto ITO one-side coated, conductive glass slides.
Each slide contained one tumor and one normal section.
The samples were dried under vacuum for 30 min and then
kept at 37°C overnight to facilitate adhesion of the section to
the target. The paraffin was removed with xylene washes
twice for 3 min each before hydration with graded ethanol
washes (100% ethanol for 2 min, 95% ethanol for 2 min
and 70% ethanol for 1 min) and then rinsed with distilled
water three times for 2 min each. After fully drying for 1 h
in an oven at 65°C, the samples were immersed into a
pre-heated steamer containing either TRIS buffer pH 9 or
citrate buffer pH 6 at 95°C for 55 min. After cooling at room
temperature for 20 min, the samples were rinsed with
distilled water three times for 5 min each. The samples were
then dried under vacuum for 30 min before matrix
application.
Matrix application
The Image Prep (Bruker Daltonics) was used for matrix
application of 10 mg/mL SA in acetonitrile/water (60:40 v/v)
containing 0.2% trifluoroacetic acid. Spraying was
accomplished using the ImagePrep standard programs.
Figure 4. (A) Average mass spectra of the tumor (red) and normal (blue) ROIs of FFPE case 1 processed with
TRIS buffer pH 9, in the m/z range of 3–15 kDa. (B) 3-D PCA plot. (C) 2-D peak distribution diagram. Specific
tumor (4476.4 m/z) and normal (3707 m/z) mass ion peaks in the mass spectra that participate in the
differentiating class of peaks are indicated by red and blue arrows.
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MALDI-IMS
Spectra were collected across selected tissue areas using an
Ultraflex III MALDI-TOF/TOF instrument (Bruker Daltonics)
with a SmartBeam laser operating at 100 Hz in positive linear
mode over the m/z range of 2000 to 20,000. A laser spot
diameter of 100 μm and a raster width of 100 μm were used.
Using the FlexImaging software (Bruker Daltonics),
orientation points were generated to ensure the correct
positioning of the laser for spectral acquisition. The software
exported the specific geometry of the tissue to be analyzed,
and an instrument-specific automated method was created,
which generates a grid across the tissue of spots upon which
data were acquired. Calibration was done externally using a
protein standard mixture in the m/z range of 3000 to 16,500.
The intensity of each scan, over the entiremass range acquired,
was mapped on to the tissue section image, allowing the
visualization of the location of each m/z value detected. These
images were generated and visualized using FlexImaging
software. Consequently, the spectra derived from regions of
interest (ROIs) were exported for profile analysis.
Normalizing, baseline subtracting, peak defining and
comparison of multiple spectra were performed using
ClinProtTools software. PCA and 2-D peak distribution were




FFPE tissue samples obtained from two prostate
adenocarcinoma cancer patients were analyzed using
MALDI-IMS and data were compared with match normal
tissues stored under the same fixation procedure. The samples
were processed using a HIAR procedure using either TRIS
buffer pH 9 or citrate buffer pH 6. FlexAnalysis software
was used to compare the different MS spectra
macroscopically. The spectra were then imported into the
ClinProTools software for post-processing and generation of
proteomic profiles. A resolution of 800was applied to the peak
detection method. The Convex Hull baseline with a flatness
value of 0.8 was selected for baseline subtraction. The Savitsky
Golay algorithm was applied with a width of 2 m/z in 5 cycles
for spectral smoothing. Null spectra exclusion filter was
enabled with a noise threshold of 2, to exclude spectra with
no data or extremely low intensities. Mass recalibration was
not performed. A schematic experimental workflow is
provided in Fig. 1.
Statistical analysis of MALDI-IMS spectra
MALDI-IMS spectra obtained from FFPE tissue sections were
submitted to PCA and 2-D distribution tests to identify mass
peaks that differentiate between normal and tumor tissue
sections. Each tumor and normal (non-tumor) tissue section
was split into different regions of interest (ROIs). The total
spectra of these ROIs were then exported to ClinProTools
software for PCA and 2-D distribution tests. PCA calculated
the variances between tumor, the adjacent normal regions
within a given specimen and normal tissue sections.
Multivariate analysis of the spectral data was repeated in both
of the analyzed cases (case 1 and case 2) using either citrate
buffer at pH 6 or TRIS buffer at pH 9 for the HIAR procedure.
Ion images of tumor and normal tissue sections of prostate
tissue (case 1) are presented in Fig. 2(A). The ROIs that were
used to perform PCA analysis and 2-D distribution tests are
highlighted. PCA revealed a series of significant ion peaks that
account for the variation between tumor and normal ROIs.
Figure 5. MALDI ion images of tumor and normal sections obtained from FFPE case 1 processed with
TRIS buffer pH 9. Distribution of selected ion peaks demonstrates the ion peaks with m/z ratios 3370,
3707, 3441 and 3447 were localized on the same areas of the tumor tissue.
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Figure 6. MALDI ion images of tumor and normal sections obtained from FFPE case 2 processed with TRIS buffer pH 6.
Average mass spectra of the tumor (red) and normal (blue) ROIs of FFPE case 2 processed with citrate buffer pH 6, in the
m/z range of 3–15 kDa.
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Score and loading outputs obtained from PCA of tumor ROIs
(T1 to T5) are presented in Fig. 2(B). The score outputs
demonstrated distinction between tumor ROIs T3 and T4
and ROIs T1, T2 and T5 in the three principal component
(PC) coordinates. This distinction is also revealed in the 2-D
peak distribution plot presented in Fig. 2(C). The PCA was
able to determine peaks that differentiated tumor ROIs T3
and T4 from normal ROIs (N1 to N4) and ROI T5 as it is
illustrated in the score and loading outputs presented in
Fig. 2(D) and the 2-D distribution diagrams presented in
Fig. 2(E). PCA between tumor ROIs T1, T2, T3 and T4 (Fig. 2(F))
discriminated ROIs T3 and T4. This distinction is also
illustrated in the 2-D peak distribution diagram presented in
Fig. 2(G). Average mass spectra of the selected ROIs and a
pseudo-gel view of the mass ion peaks obtained from PCA,
all in the mass range 3–15 kDa, are presented in Figs. 3(A)
and 3(B), respectively. Several mass ion peaks demonstrated
distinction between tumor and normal ROIs and revealed
the heterogeneity of tumor tissue sections. In particular, mass
ion peaks at m/z 3369.8, 3440.7, 3484.7, 3707.9, 3719.2 and
13880.6 were overexpressed in tumor ROIs T3 and T4, mass
ion peaks at m/z 3455.1, 4027.3 6283.1, 6643.4, 6656.2 and
6997.2 were more evident in ROIs T1 and T2 indicating tumor
heterogeneity, while mass ion peaks at m/z 6013.1 and 6017.8
were overexpressed in normal ROIs. Tumor ROIs T3 and
T4 have been further combined in one class using
ClinProtSpectra import XML generator and compared with
normal ROIs. A series of mass ion peaks that account for the
variation between normal and tumor FFPE tissue sections
can be observed in Fig. 4(A) where the average mass spectra
of tumor and normal ROIs, in the mass range 3–15 kDa, are
presented. This distinction between tumor and normal ROIs
is further revealed in the 3-D PCA plot and the 3-D peak
distribution diagram presented in Figs. 4(B) and 4(C),
respectively. The arrows in the 3-D loading plots presented
in Fig. 4(C) indicate the placement of the mass ion peak at
m/z 3707 which is overexpressed in tumor regions and the
placement of the mass ion peak at m/z 4476 which is more
evident in normal regions. Multivariate data analysis was
repeated, as described above, in both FFPE cases studied.
PCA of the spectral data revealed a series of significant ion
peaks that account for the variation between tumor and
normal tissue. Differentially expressed ion peaks have been
ranked according to their signal-to-noise ratio using p-value
t-test analysis of variance (ANOVA) (Table 1). Mass ion peaks
with m/z values of 3370, 3441, 3477, 5999, 6013, 6028, 6272,
6643, 6656, 6684, 6698 and 6799 appeared in both FFPE cases
and independently of the buffer used for the HIAR procedure.
The ion peaks with p-values less than 0.05 have been used to
generate ion images and visualize the difference between
tumor and normal ROIs. Among these molecular images,
mass ion peaks atm/z 3370, 3441, 3447 and 3707 were detected
to have stronger ion signals within tumor ROIs and could be
used to distinguish prostate cancer tissue from normal
prostate tissue.
Figure 5 illustrates MALDI ion images of tumor and normal
FFPE tissue sections of case 1 processed with TRIS buffer pH 9
for the HIAR procedure using these distinct mass ion peaks.
The spatial distribution of each of these ion peaks illustrated
significant changes in intensity and varying distribution
patterns among the different ROIs. Average mass spectra of
tumor and normal ROIs in case 2 processed in citrate buffer
pH 6 in the m/z range of 3–15 kDa and MALDI ion images of
the selected mass ion peaks that differentiate between normal
and tumor tissue sections at m/z 3370, 3441, 3471, 4836, 6013
and 6272 are presented in Fig. 6.
Our findings are in accordance with some of the MALDI-
IMS data presented in other studies. In MALDI-MS profiling
of human serum samples, Fania and coworkers recently found
an overexpression of the ion peaks at m/z 3448.63 and 6809.47
when compared with matched normal samples, which
correlates with the ion peaks at m/z 3441 and 6799 detected
in our study.[23] The mass ion peak at m/z 3441 was also
detected with increased expression in cancerous regions of
fresh-frozen prostate tissues in aMALDI-IMS study presented
by Schwamborn and coworkers.[28] In the latter study one
other ion peak at m/z 4747 showed a slight overexpression in
the cancerous regions, which agrees with the ion peak at m/z
4836 found in the FFPE prostate tissues analyzed in this work.
Calvano and coworkers found that the MALDI-MS signal
intensity at m/z 6290 was higher for PCa urine samples when
compared to healthy individuals, which agrees with the ion
peak at m/z 6272 found in our study.[24] MALDI-IMS analysis
of fresh-frozen tissues by Klocker and coworkers identified
characteristic mass ion peaks that were able to discriminate
between cancer, non-malignant benign epithelium and
stromal areas ROIs.[31] In particular, mass ion peaks at m/z
4468, 6266 6284 and 6658 showed discriminatory ability to
separate tumor areas versus benign epithelial non-malignant
areas, a mass ion peak at m/z 3440 was also detected with
increased expression in cancerous regions versus stromal
areas and mass ion peaks at m/z 6284 and 6658 are
discriminant for tumor versus stromal ROIs. The mass ion
peak atm/z 6658 was identified in the same study as biliverdin
reductase B (BLVRB). BLVR subtype B is the major heme
catabolizing enzyme during early fetal development and
BLVR subtype A the major form of BLVR in the adult human
liver.[48] In our study mass ion peaks at m/z 3441, 4476, 6271,
6283 and 6656 were also identified as discriminant peaks
between tumor andnormal ROIs of FFPE tissue sectionswhich
indicates that the proposed method can reveal the proteomic
profile of prostate tissues and that the sequential PCA used
in this work is able to easily detect possible biomarkers for
PCa. However, it should be noted that mass differences
between publications can be either explained by pre-analytical
molecular changes, low-quality data acquisition, different
biological matrix used for the analysis or closely related
quasi-molecular ions due to reactions during sample
preparation, adduct ion formation or the loss of smaller
functional groups.[26]
CONCLUSIONS
The findings of this study demonstrate that multivariate
analysis of MALDI-IMS data revealed a series of mass ion
peaks that allowed the visualization of tumor ROIs and more
importantly the ability to differentiate between tumor and
normal ROIs in FFPE prostate tissue biopsies. Furthermore,
PCA was able to differentiate specific mass ion peaks from
different tumor regions within the same tissue defining the
presence of tissue heterogeneity in FFPE prostate cancer
specimens. The identification of the mass ion peaks
responsible for the tissue heterogeneity within a prostate
I. Panderi et al.
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cancer specimen is of potential therapeutic interest and might
play a key role in the understanding of the etiology of the
disease. These mass ion peaks are probably a result of the
molecular differences between different states of the disease.
The results highlight the degree of tumor heterogeneity
inherent in prostate cancer biopsies. However, MALDI-IMS
technology is challenging to directly detect high molecular
mass biomarkers, with molecular mass greater than 25 kDa,
that are currently used in clinical cancer research.[49]
Therefore, the mass ion peaks detected in this pilot study
represent low molecular weight biomolecules that can be
fragments of peptides or proteins which are up-regulated in
prostate cancer and may play a role in signaling pathways of
this disease. The detected mass ion peaks can differentiate
between the tumor and normal regions and their identification
may provide insight into new important therapeutic targets.
This study provides evidence in support of the clinical utility
of MALDI-IMS which is able to annotate tissues based solely
on the detected MS profiles and thereby differentiate regions
that are not distinct using established histopathological tools
but which are characterized by different MS signatures. This
ability to effectivelydefine tumor regionsbymolecular profiling
at high resolution will provide a greater understanding of
molecular mechanisms of tumor heterogeneity and warrants
further studies for the identification of the most significant
peaks. Furthermore, enrollment of a larger patient group will
allow a better comparison of clinical and histopathological
data using MALDI-IMS.
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